On April 26, 2022, ShiftBio, a leader in the development of innovative exosome platform technologies, announced a strategic partnership with RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cells (MSCs), highly engineered media, and bioprocess development services. This partnership will accelerate ShiftBio's therapeutic candidates, starting with SBI-102 (stem cell-derived exosomes expressing a therapeutic ligand), into the clinic. Through this partnership, RoosterBio will develop a cGMP manufacturing process designed to meet the needs for Phase I/II clinical trials, with the ability to scale as needed for Phase III and commercial production. RoosterBio will design and execute all process development studies, leveraging its industry-leading cell and media product portfolio.
ShiftBio Partners with RoosterBio to Accelerate Development of a Novel Genetically Engineered Exosome (SBI-102) for Currently Untreatable Disease Indications
Login Or Register To Read Full Story